Moderna COVID-19 vaccine

Phase 3Vaccine

Moderna

Moderna COVID-19 vaccine is one of 74 biologic programs targeting Autoimmune Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

COVID-19Active, not recruiting

Autoimmune DiseasePhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Moderna COVID-19 vaccine

Moderna

Phase 3

4 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Post-ApprovalRecruiting

COVID-19

NCT06441955

Clinical

Trials by Indication[1]

COVID-194 trials

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

Completed· Moderna logo

Moderna··NCT05765578·1,713 enrolled

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Recruiting·WWell- Konnect Healthcare Services and Research Firm·Phase 4·NCT06441955·100 enrolled

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

Completed·PPT Bio Farma··NCT06006858·1,284 enrolled

Show 1 more trial

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04811664·1,923 enrolled

Autoimmune Disease1 trial

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT04806113·220 enrolled

Vaccination1 trial

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04761822·746 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Moderna COVID-19 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moderna COVID-19 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moderna COVID-19 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Moderna

Moderna COVID-19 vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

COVID-194 trials

Autoimmune Disease1 trial

Vaccination1 trial

References

Drug Info

Quick Facts

Related News